OXNARD, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company researching cannabinoid molecules for various healthcare applications, announced today the appointment of industry veteran Richard S. Serbin to its senior management team as Head of Global Corporate Development.
As a 40-plus year healthcare industry veteran, with expertise in licensing medical extracts, compounds, and technologies, Serbin will play a strategic role in helping CURE’s expansion into the booming medical cannabinoid area as well as new partnerships around this industry.
“I am delighted to welcome Richard to the CURE senior management team,” said Rob Davidson, CEO of CURE. “The addition of Richard comes at a pivotal time for our organization as we continue to grow and embark on bringing new cannabinoid molecules to market and developing a global footprint in the pharmaceutical cannabis sector. Richard has impressive and extensive experience throughout the pharmaceutical industry, plus has served as a consultant to Government Agencies developing policies with regard to the approval and marketing of medical cannabis. We look forward to utilizing his specific knowledge advising private and public companies engaged in the growth, extraction, regulatory approval and marketing of medical cannabis.”
Serbin, who previously held the position of Vice President of Corporate Development for Johnson & Johnson, has served on the Board of Directors of 16 subsidiary companies for Johnson & Johnson, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He also served as Director at Viropro, Rapid Nutrition Plc. and Optigenex.
In addition, Serbin headed Corporate Development and in-house legal counsel at Life Science Institute, LLC. He is a global strategy advisor and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry, with more than 25 years of experience in the pharmaceutical industry and the investment community. Founder of Radius Scientific Corporation, he also served as CEO of Optigenex Inc. and president of Bradley Pharmaceuticals, and in multiple capacities at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, Revlon and Schering-Plough. In addition, he served as a consultant to various pharmaceutical companies.
“I am pleased to have the opportunity to work with the management team at CURE during this pivotal growth stage of the Company,” said Serbin. “With its innovative and advanced portfolio of drug platform delivery systems, CURE is uniquely positioned to partner with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. Additionally, I look forward to advancing CURE’s leadership role in optimizing plant base cannabinoids by utilizing my over 40-plus years as an FDA regulatory and patent attorney to assist CURE in bringing new cannabinoid molecules to the market through the FDA regulatory approval process.”
Serbin also plays an active role in developing business strategy and joint venture contacts and in guiding Mazal Plant Pharmaceuticals Inc. in regulatory compliance and investor relations. He has been head of its Business Advisory Board. In addition, for the last 10 years, Serbin has been a senior advisor to the Swedish American Life Science Summit, held annually in Stockholm, Sweden.
He holds undergraduate degrees from Rutgers University and Rutgers University College of Pharmacy, a Juris Doctor degree from Seton Hall Law School and a Master’s degree in Trade Regulations and Law from New York University Law School.
About CURE Pharmaceutical
Cure Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs). Cure has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. Cure has developed an array of products in cutting-edge delivery platforms. Cure is well positioned in the pharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Andrew Hard CMW Media Andrew.email@example.com 917.660.5418